The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Human iPSCs-Global Market Insights and Sales Trends 2024
Synopsis
The global Human iPSCs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human iPSCs in various end use industries. The expanding demands from the Academic Research, Drug Development and Discovery, Toxicity Screening and Regenerative Medicine, are propelling Human iPSCs market. Skin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Blood Cells segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Human iPSCs market, driven by demand from China, the second largest economy with some signs of stabilising, the Human iPSCs market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human iPSCs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human iPSCs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human iPSCs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human iPSCs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human iPSCs covered in this report include Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology and ReproCELL, etc.
The global Human iPSCs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL
Global Human iPSCs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human iPSCs market, Segment by Type:
Skin
Blood Cells
Global Human iPSCs market, by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Human iPSCs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Human iPSCs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human iPSCs in various end use industries. The expanding demands from the Academic Research, Drug Development and Discovery, Toxicity Screening and Regenerative Medicine, are propelling Human iPSCs market. Skin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Blood Cells segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Human iPSCs market, driven by demand from China, the second largest economy with some signs of stabilising, the Human iPSCs market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human iPSCs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human iPSCs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human iPSCs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human iPSCs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human iPSCs covered in this report include Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology and ReproCELL, etc.
The global Human iPSCs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL
Global Human iPSCs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human iPSCs market, Segment by Type:
Skin
Blood Cells
Global Human iPSCs market, by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Human iPSCs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Human iPSCs
1.1 Human iPSCs Market Overview
1.1.1 Human iPSCs Product Scope
1.1.2 Human iPSCs Market Status and Outlook
1.2 Global Human iPSCs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Human iPSCs Market Size by Region (2018-2029)
1.4 Global Human iPSCs Historic Market Size by Region (2018-2023)
1.5 Global Human iPSCs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Human iPSCs Market Size (2018-2029)
1.6.1 North America Human iPSCs Market Size (2018-2029)
1.6.2 Europe Human iPSCs Market Size (2018-2029)
1.6.3 Asia-Pacific Human iPSCs Market Size (2018-2029)
1.6.4 Latin America Human iPSCs Market Size (2018-2029)
1.6.5 Middle East & Africa Human iPSCs Market Size (2018-2029)
2 Human iPSCs Market by Type
2.1 Introduction
2.1.1 Skin
2.1.2 Blood Cells
2.2 Global Human iPSCs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Human iPSCs Historic Market Size by Type (2018-2023)
2.2.2 Global Human iPSCs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Human iPSCs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Human iPSCs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Human iPSCs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Human iPSCs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Human iPSCs Revenue Breakdown by Type (2018-2029)
3 Human iPSCs Market Overview by Application
3.1 Introduction
3.1.1 Academic Research
3.1.2 Drug Development and Discovery
3.1.3 Toxicity Screening
3.1.4 Regenerative Medicine
3.1.5 Others
3.2 Global Human iPSCs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Human iPSCs Historic Market Size by Application (2018-2023)
3.2.2 Global Human iPSCs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Human iPSCs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Human iPSCs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Human iPSCs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Human iPSCs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Human iPSCs Revenue Breakdown by Application (2018-2029)
4 Human iPSCs Competition Analysis by Players
4.1 Global Human iPSCs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human iPSCs as of 2022)
4.3 Date of Key Players Enter into Human iPSCs Market
4.4 Global Top Players Human iPSCs Headquarters and Area Served
4.5 Key Players Human iPSCs Product Solution and Service
4.6 Competitive Status
4.6.1 Human iPSCs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Fujifilm Holding Corporation (CDI)
5.1.1 Fujifilm Holding Corporation (CDI) Profile
5.1.2 Fujifilm Holding Corporation (CDI) Main Business
5.1.3 Fujifilm Holding Corporation (CDI) Human iPSCs Products, Services and Solutions
5.1.4 Fujifilm Holding Corporation (CDI) Human iPSCs Revenue (US$ Million) & (2018-2023)
5.1.5 Fujifilm Holding Corporation (CDI) Recent Developments
5.2 Ncardia
5.2.1 Ncardia Profile
5.2.2 Ncardia Main Business
5.2.3 Ncardia Human iPSCs Products, Services and Solutions
5.2.4 Ncardia Human iPSCs Revenue (US$ Million) & (2018-2023)
5.2.5 Ncardia Recent Developments
5.3 Sumitomo Dainippon Pharma
5.3.1 Sumitomo Dainippon Pharma Profile
5.3.2 Sumitomo Dainippon Pharma Main Business
5.3.3 Sumitomo Dainippon Pharma Human iPSCs Products, Services and Solutions
5.3.4 Sumitomo Dainippon Pharma Human iPSCs Revenue (US$ Million) & (2018-2023)
5.3.5 Astellas Pharma Inc Recent Developments
5.4 Astellas Pharma Inc
5.4.1 Astellas Pharma Inc Profile
5.4.2 Astellas Pharma Inc Main Business
5.4.3 Astellas Pharma Inc Human iPSCs Products, Services and Solutions
5.4.4 Astellas Pharma Inc Human iPSCs Revenue (US$ Million) & (2018-2023)
5.4.5 Astellas Pharma Inc Recent Developments
5.5 Fate Therapeutics, Inc
5.5.1 Fate Therapeutics, Inc Profile
5.5.2 Fate Therapeutics, Inc Main Business
5.5.3 Fate Therapeutics, Inc Human iPSCs Products, Services and Solutions
5.5.4 Fate Therapeutics, Inc Human iPSCs Revenue (US$ Million) & (2018-2023)
5.5.5 Fate Therapeutics, Inc Recent Developments
5.6 Pluricell Biotech
5.6.1 Pluricell Biotech Profile
5.6.2 Pluricell Biotech Main Business
5.6.3 Pluricell Biotech Human iPSCs Products, Services and Solutions
5.6.4 Pluricell Biotech Human iPSCs Revenue (US$ Million) & (2018-2023)
5.6.5 Pluricell Biotech Recent Developments
5.7 Cell Inspire Biotechnology
5.7.1 Cell Inspire Biotechnology Profile
5.7.2 Cell Inspire Biotechnology Main Business
5.7.3 Cell Inspire Biotechnology Human iPSCs Products, Services and Solutions
5.7.4 Cell Inspire Biotechnology Human iPSCs Revenue (US$ Million) & (2018-2023)
5.7.5 Cell Inspire Biotechnology Recent Developments
5.8 ReproCELL
5.8.1 ReproCELL Profile
5.8.2 ReproCELL Main Business
5.8.3 ReproCELL Human iPSCs Products, Services and Solutions
5.8.4 ReproCELL Human iPSCs Revenue (US$ Million) & (2018-2023)
5.8.5 ReproCELL Recent Developments
6 North America
6.1 North America Human iPSCs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Human iPSCs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Human iPSCs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Human iPSCs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Human iPSCs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Human iPSCs Market Dynamics
11.1 Human iPSCs Industry Trends
11.2 Human iPSCs Market Drivers
11.3 Human iPSCs Market Challenges
11.4 Human iPSCs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
